Robert Penland

Robert Penland

Auto-generated profile, based on publicly available information

Robert Penland

Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2014 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
DBDieter Becker
Dieter Becker
JZJin Zhang
Jin Zhang
THTycho Heimbach
Tycho Heimbach
RPRobert C. Penland
Robert C. Penland
CWChristoph Wanke
Christoph Wanke
KKKenneth Kulmatycki
Kenneth Kulmatycki
Typically, colonic absorption of a drug is mandatory for a sustained release formulation to hold the drug’s plasma level for more than 12 or 24&n

14 May 2019 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
GHGabriel Helmlinger
Gabriel Helmlinger
VSVictor Sokolov
Victor Sokolov
KPKirill Peskov
Kirill Peskov
KHKaren M. Hallow
Karen M. Hallow
YKYuri Kosinsky
Yuri Kosinsky
RPRobert C. Penland
Robert C. Penland
Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and clinical data. Likewise, the available modeling techniques and related software tools are manifold. Appropriately, the development, qualification, application, and impact of QSP models have been similarly varied. In this review, we describe the progressive maturation of a QSP modeling workflow: a necessary step for the efficient, reproducible development and qualification of QSP models, which themselves are highly iterative and evolutive. Furthermore, we describe three applications of QSP to impact drug development; one supporting new indications for an approved antidiabetic clinical asset through mechanistic hypothesis generation, one highlighting efficacy and safety differentiation within the sodium‐glucose cotransporter‐2 inhibitor drug class, and one enabling rational selection of immuno‐oncology drug combinations.

1 January 2006 in Progress in Biophysics and Molecular Biology
Verified
Journal Article
Closed access
DBD Bottino
D Bottino
RPR Penland
R Penland
ASA Stamps
A Stamps
MTM Traebert
M Traebert
BDB Dumotier
B Dumotier
GLG Lett
G Lett

1 July 2002 in Computing and Visualization in Science
Verified
Journal Article
Closed access
PDF file
RPR. Christian Penland
R. Christian Penland
DHDavid M. Harrild
David M. Harrild
CHCraig S. Henriquez
Craig S. Henriquez

1 January 2012 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
GEGül Erdemli
Gül Erdemli
AKAlbert M. Kim
Albert M. Kim
HJHaisong Ju
Haisong Ju
CSClayton Springer
Clayton Springer
RPRobert C. Penland
Robert C. Penland
PHPeter K. Hoffmann
Peter K. Hoffmann
The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for action potential generation and propagation in the heart. Drug-induced sodium channel inhibition decreases the rate of cardiomyocyte depolarization and consequently conduction velocity and can have serious implications for cardiac safety. Genetic mutations in hNav1.5 have also been linked to a number of cardiac diseases. Therefore, off-target hNav1.5 inhibition may be considered a risk marker for a drug candidate. Given the potential safety implications for patients and the costs of late stage drug development, detection, and mitigation of hNav1.5 liabilities early in drug discovery and development becomes important. In this review, we describe a pre-clinical strategy to identify hNav1.5 liabilities that incorporates in vitro, in vivo, and in silico techniques and the application of this information in the integrated risk assessment at different stages of drug discovery and development.

16 February 2020 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
VSVictor Sokolov
Victor Sokolov
TYTatiana Yakovleva
Tatiana Yakovleva
LCLulu Chu
Lulu Chu
WTWeifeng Tang
Weifeng Tang
PGPeter J. Greasley
Peter J. Greasley
RPRobert C. Penland
Robert C. Penland
The aim of this research was to differentiate dapagliflozin, empagliflozin, and canagliflozin based on their capacity to inhibit sodium‐glucose cotransporter (SGLT) 1 and 2 in patients with type 2 diabetes using a previously developed quantitative systems pharmacology model of renal glucose filtration, reabsorption, and excretion. The analysis was based on pooled, mean study‐level data on 24‐hour urinary glucose excretion, average daily plasma glucose, and estimated glomerular filtration rate collected from phase I and II clinical trials of SGLT2 inhibitors. Variations in filtered glucose across clinical studies were shown to drive the apparent differences in the glucosuria dose–response relationships among the gliflozins. A normalized dose–response analysis demonstrated similarity of dapagliflozin and empagliflozin, but not canagliflozin. At approved doses, SGLT1 inhibition by canagliflozin but not dapagliflozin or empagliflozin contributed to ~ 10% of daily urinary glucose excretion.